Navigation Links
Johnson & Johnson and Synthes Announce Definitive Merger Agreement to Create World's Most Innovative and Comprehensive Orthopaedics Business
Date:4/26/2011

NEW BRUNSWICK, N.J. and WEST CHESTER, Pa., April 27, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), the world's most comprehensive and broadly-based manufacturer of health care products, and Synthes, Inc. (SWX:SYST.VX), a premier global manufacturer of orthopaedic devices, today announced that they have entered into a definitive agreement whereby Johnson & Johnson will acquire Synthes for CHF159 per share, or $21.3 billion.  Upon completion of this transaction, Synthes and the DePuy Companies of Johnson & Johnson together will comprise the largest business within the Medical Devices and Diagnostics segment of Johnson & Johnson.  

Under the terms of the agreement, each share of Synthes common stock, subject to certain conditions, will be exchanged for CHF55.65 in cash and CHF103.35 in Johnson & Johnson common stock. The transaction has an estimated net acquisition cost of $19.3 billion as of the close of business on April 26, 2011, based on Synthes approximately 119.5 million fully diluted shares outstanding and approximately $2 billion in cash on hand as of signing.

The Boards of Directors of Johnson & Johnson and Synthes have each approved the transaction. Dr. Hansjoerg Wyss, Synthes founder and Chairman of the Board, and related parties have agreed to vote shares representing not less than 33% of Synthes common stock in support of the transaction.

DePuy offers one of the most diverse orthopaedics portfolios in the industry, while Synthes is recognized for its innovations in trauma, spine, cranio-maxillofacial and power tools.  Together, the companies will offer surgeons and patients a unique breadth and depth of technology and service worldwide to meet their orthopaedic needs.

"DePuy and Synthes together will create the most innovative and comprehensive orthopaedics business in the world and enable us to bett
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
2. Johnson & Johnson Reports 2011 First-Quarter Results
3. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
4. AFSCME Urges Shareholders to Vote against Executive Compensation at Pfizer (PFE) and Johnson & Johnson (JNJ)
5. Johnson & Johnson Announces Settlement With U.S. Department of Justice and U.S. Securities and Exchange Commission
6. Woman Files Suit in Beaumont, Texas Federal Court Against DePuy Orthopaedics and Johnson & Johnson Over Recalled Hip Device
7. Woman Files Suit in Federal Court Against DePuy Orthopaedics, Inc.,/Johnson & Johnson Over Recalled Hip Device
8. Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
9. Johnson & Johnson to Participate in 2011 Citi Global Health Care Conference
10. Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
11. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Research and Markets ( ... "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services ... Asia Pacific Version" report to their offering. ... growing. Clinical laboratory testing is positioned to directly ... A range of dynamic trends are pushing market ...
(Date:5/5/2015)... state at a time, more cannabis entrepreneurs are coming up with brilliant ways to help cannabis business solve problems and capitalize ... ... ... ... Photo - ...
(Date:5/5/2015)... 5, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... randomized, double-blinded, placebo-controlled Phase 2 clinical trial of ... in combination with nab-paclitaxel and gemcitabine, versus nab-paclitaxel ... pancreatic cancer who have high serum levels of ... fourth leading cause of cancer death in ...
Breaking Medicine Technology:Asia Pacific Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Report 2015-2019 2Top Ten Ways Cannabis Startups are Getting Funded 2Top Ten Ways Cannabis Startups are Getting Funded 3Top Ten Ways Cannabis Startups are Getting Funded 4Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4
... ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, ... company developing medical countermeasures against biological and chemical threats, ... call for investors on Wednesday, April 29th beginning at ... rPA anthrax vaccine program. The dial-in number within the ...
... Urological Association Annual Meeting --SEATTLE and CHICAGO, April ... DNDN ) today presented preclinical data demonstrating ... molecule, which targets TRPM8 (a transmembrane cation channel ... D-3263 demonstrated the ability to reduce BPH alone ...
Cached Medicine Technology:PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program 2Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 4
(Date:5/5/2015)... global lab automation market is expected to reach $5,105.7 ... an estimated CAGR of 6.7% from 2015 to 2020. ... basis of equipment and software, application, type of automation, ... Lab Automation Market is classified into clinical diagnostics, drug ... a major application of the lab automation market. Developing ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 The newly minted ... the experiences of Dr. Brad Reedy from his 20 ... Regan was asked why she chose to publish a parenting book ... a parent (and publisher) is the idea that it is a ... and our children are on the trek sometimes together and sometimes ...
(Date:5/5/2015)... Atlanta, Georgia (PRWEB) May 05, 2015 ... Software of Victoria BC announced the Skedans Sensor ... The platform, for mobile and web app developers, provides ... from airborne and mobile sensors. , The Skedans Sensor ... at the intersection of the Internet of Things, Web ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 ... mission-focused company serving the federal government, today announced ... (CCSi). CCSi provides solutions exclusively to federal ... extensive experience in cyber security, health services, and ... processes and industry-relevant credentials as a Third Party ...
(Date:5/5/2015)... SC (PRWEB) May 05, 2015 On May, ... episode with Charleston musician Irene Rose about alternatives for youngsters ... Rose, “How did you get the idea for starting a ... replies, “I run an entertainment company called Once Upon a ... them moral lessons through songs and even scripture. We play ...
Breaking Medicine News(10 mins):Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2
... doesn,t have excess stomach acid, study finds, , , MONDAY, ... anti-reflux medications to infants, new research suggests. , The ... given anti-reflux medications, which work by lowering levels of ... four out of five infants included in the study ...
... Introduces Simplified Issue Underwriting for Return of Premium ... make the purchase of life,insurance easier and more ... simplified issue underwriting process for its Return of,Premium ... amounts from,$100,000 to $249,999. "ROP Term with Simplified ...
... Two nonprofit,foundations devoted to the support, treatment and ... as "Fragile X" have,agreed to a formal merger as ... (NFXF) and Florida-based Conquer Fragile X,Foundation (CFXF) will now ... X community. The agreement calls for the NFXF ...
... Associates has been,awarded a $15 million, 7-year contract ... the U.S. Department of Health and Human Services,Administration ... major evaluation,of employment and self-sufficiency programs. The programs ... for Needy Families,(TANF) benefits, as well as families ...
... Inpatient Certification ... ... Siemens Medical,Solutions (http://www.usa.siemens.com/healthcareit ) today announced that,Soarian(R) Clinicals V2.0C5 ... conditionally CCHIT Certified(sm),status from the Certification Commission for Healthcare Information,Technology ...
... 5, 2007 Human Genome Sciences, Inc. (Nasdaq: ... a Phase 2b clinical trial of the investigational ... in treatment-naive patients with genotype 1 chronic hepatitis ... Albuferon treatment groups reported fewer missed days of ...
Cached Medicine News:Health News:Anti-Reflux Drugs May Be Overprescribed in Infants 2Health News:Anti-Reflux Drugs May Be Overprescribed in Infants 3Health News:AXA Equitable Makes it Easier to Stop Ignoring Life Insurance 2Health News:AXA Equitable Makes it Easier to Stop Ignoring Life Insurance 3Health News:AXA Equitable Makes it Easier to Stop Ignoring Life Insurance 4Health News:Fragile X Foundations Sign Merger Agreement 2Health News:Fragile X Foundations Sign Merger Agreement 3Health News:Abt Associates to Lead Major Evaluation of Programs Aimed at Promoting Self-Sufficiency for Disadvantaged Families 2Health News:Siemens Medical Solutions Receives CCHIT Certification for Soarian Clinicals With Siemens Pharmacy and Med Administration Check 2Health News:Siemens Medical Solutions Receives CCHIT Certification for Soarian Clinicals With Siemens Pharmacy and Med Administration Check 3Health News:Siemens Medical Solutions Receives CCHIT Certification for Soarian Clinicals With Siemens Pharmacy and Med Administration Check 4Health News:HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C 2Health News:HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C 3
Inquire...
Inquire...
Agarose I (Molecular Biology Grade) - A regular melting temperature agarose for electrophoresis requiring an exceptional level of purity with unequaled performance....
... a premium agarose used for isolating DNA ... produces clear sharp bands, with no smearing ... UltraClean Forensic Agarose is tested and certified ... activity and DNA contamination. Meets ...
Medicine Products: